Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

HCV Virions Bound Proteins

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02795403
Recruitment Status : Completed
First Posted : June 10, 2016
Last Update Posted : June 10, 2016
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

The emergence of hepatocellular carcinoma (HCC) has prompted a search for a thorough understanding of the biology of one of its major causative agents, the hepatitis C virus (HCV). HCV particles acquire via budding and encapsidation cellular proteins. There is mounting evidence on several viral species that virion-bound proteins are prone to be involved either at the replication, budding/egress or entry/release steps of the viral cycle.

Identifying such targets may yield ideal candidates for gaining insight on the dependence of HCV upon a restricted subset of host proteins, therefore providing refined sets of genetically stable targets for therapy. This project's goals are to set up adequate conditions for robust and reproducible purification of HCV virions in clinical samples, followed by the identification of their HCV-bound host proteins and the characterization of their functions. Proteomics profiling of HCV particles purified from clinical samples will be overlaid with proteins identified and characterized in cell culture grown HCV particles during my post-doctoral training, using clinical biomarker discovery grade criteria. Targets identified in both samples sets will be subjected to in vitro investigations using HCV-replicating cells. Conventional biochemical and imaging methods will be used in order to: (i) ascertain their physical association with HCV virions; (ii) define the modalities of their interaction with HCV proteins; (iii) decipher the topology and subcellular localization of their association with HCV proteins and virions; (iv) quantitatively assess their functional involvement in particle budding, egress or secretion and infectivity. A candidate that yielded satisfactory results in these experiments will be disclosed and further investigated at the level of structural biology, in collaborative research programs.


Condition or disease Intervention/treatment Phase
Hepatitis C Other: blood draw of 150ml, twice Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Basic Science
Official Title: Hepatitis C Virus Particles-bound Human Proteins : Identification in Clinical Samples and Implication in the Viral Life Cycle
Study Start Date : January 2011
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Viraemic Other: blood draw of 150ml, twice
Experimental: responder group Other: blood draw of 150ml, twice



Primary Outcome Measures :
  1. Qualitative identification (unit used: Protein Prophet score) of a given virion-bound protein in purified virions preparations [ Time Frame: One to two years after mass spectrometry identification of the candidate ]
    Protein prophet scores allow one to estimate the robustness of identification of a given protein in MS approaches.

  2. Quantitative evaluation of its implication in viral morphogenesis (unit used: TCID50). [ Time Frame: One to two years after mass spectrometry identification of the candidate ]
    TCID50 units are infectivity units routinely used in HCV research for viral infectivity quantification.

  3. Quantitative evaluation of viral entry (unit used: HCV RNA /GUS mRNA copy ratios). [ Time Frame: One to two years after mass spectrometry identification of the candidate ]
    HCV RNA /GUS mRNA copy ratios are derived from the 2^delta(delta Ct) method.


Secondary Outcome Measures :
  1. Comparison of clinical virions datasets with in vitro grown virions datasets [ Time Frame: One to two years after mass spectrometry identification of the candidate ]
    Proteins identified from viral particles purified from clinical samples will be compared to proteins identified in viral particles from cells of human hepatocarcinoma (Huh7.5) infected with HCV and from which data are published.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult> 18 and <60 years
  • Infected with HCV genotype 1 HCV antibody positive.
  • positive viremia for more than 6 months
  • Viremia> 106 IU / ml.
  • nonresponders to previous treatment and without antiviral treatment for 2 months.
  • For control samples: Patients responders to previous treatment and without antiviral treatment for 2 months.

Exclusion Criteria:

  • Patient receiving or having received antiviral treatment within two months.
  • patient with against-indication for a blood sample of 150 ml
  • immunosuppressive therapy patient
  • Patient with liver disease other than hepatitis C.
  • Patients with cirrhosis.
  • patient with hepatocellular carcinoma.
  • Patients with one or more severe co-morbidities defined as:
  • Co-infection with HIV or HBV.
  • hematological malignancies changing or aplasia
  • Insulin-dependent diabetes
  • dialyzed chronic renal failure
  • Heart failure
  • Persons subject to legal protection or the subject of a safeguard measure of justice not affiliated with a social security scheme or not beneficiaries of such a scheme
  • Pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02795403


Locations
Layout table for location information
France
Service d'Hépato-Gastroentérologie Lyon Croix-Rousse Hospices Civils de Lyon
Lyon, France, 69004
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Layout table for investigator information
Principal Investigator: Fabien ZOULIM, MD Service d'Hépato-Gastroentérologie Lyon Croix-Rousse Hospices Civils de Lyon
Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT02795403    
Other Study ID Numbers: 2009-596
First Posted: June 10, 2016    Key Record Dates
Last Update Posted: June 10, 2016
Last Verified: May 2016
Keywords provided by Hospices Civils de Lyon:
HCV, liver
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis C
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
RNA Virus Infections
Flaviviridae Infections